Genprex

Tagged: lung cancer

Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers

The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.

Read More

Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

AUSTIN, Texas & CAMBRIDGE, Mass.— (November 4, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month.

Each patient’s cancer is unique, but there are some preventive efforts that can be made to lower the risk of getting lung cancer….

Read More

5 Things to Know about Lung Cancer Treatment

Cancer is a complex disease that can be difficult treat. Lung cancer specifically is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver or prostate cancers.

Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is researching and developing therapies for the treatment of lung cancer….

Read More

IASLC 2019: Bringing Together Collaboration, Science and Hope for the Future

Last month, Genprex’s President and Chief Operating Officer, Julien Pham, attended the IASLC 2019 Targeted Therapies of Lung Cancer Meeting in Santa Monica, California. This meeting brought together a variety of key players working on the newest therapies for lung cancer including researchers, oncologists, physicians, patient advocacy groups and even clinical-stage companies, such as Genprex….

Read More